Recorlev®

February 18, 2022
For Professionals|Podcasts|

In today’s podcast directed to physicians, PWN co-founder Dr. Lewis Blevins discusses the drug Recolev® (levoketoconazole) recently approved by the FDA to treat endogenous Cushing’s Syndrome.

In today’s podcast directed to physicians, PWN co-founder Dr. Lewis Blevins discusses the drug Recorlev® (levoketoconazole) recently approved by the FDA to treat endogenous Cushing’s Syndrome. While this podcast contains medical and technical terminology, we encourage patients to listen to it and discuss it with their physicians.

 

Music by REDproductions®[/vc_column_text][/vc_column][/vc_row]

© 2022 – 2024, Pituitary World News. All rights reserved.

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *